2219P AGITG ASCEND: Randomised, double-blind phase II trial of certepetide (CERT) or placebo (PLA) with gemcitabine (Gem) + nab-paclitaxel (Nab) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated results including planned pooled placebo analysis
Saved in:
| Title: | 2219P AGITG ASCEND: Randomised, double-blind phase II trial of certepetide (CERT) or placebo (PLA) with gemcitabine (Gem) + nab-paclitaxel (Nab) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated results including planned pooled placebo analysis |
|---|---|
| Authors: | Dean, A.1 (AUTHOR), Harris, M.T.2 (AUTHOR), Sjoquist, K.3 (AUTHOR), Gebski, V.4 (AUTHOR), Karapetis, C.S.5 (AUTHOR), Lomma, C.6 (AUTHOR), Burge, M.7 (AUTHOR), Steer, C.8 (AUTHOR), Tebbutt, N.9 (AUTHOR), Lee, B.10 (AUTHOR), Jackson, C.11 (AUTHOR), Day, F.12 (AUTHOR), Padinharakam, S.13 (AUTHOR), Murray, J.14 (AUTHOR), Buck, K.K.15 (AUTHOR), Mumford, J.V.16 (AUTHOR), Siu, D.17 (AUTHOR), Lee, J.18 (AUTHOR), Gao, Y.R.19 (AUTHOR), Price, T.J.20 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1233-S1234. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2836 |
